Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $48.79 indicates a 34.4% upside potential. The mean estimate comprises 14 short-term price targets with a standard deviation of $20.54. While the lowest estimate of $26 indicates a 28.4% decline from the current price level, the most optimistic analyst expects the stock to surge 208.5% to reach $112. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. But, for KYMR, an impressive average price target is not the only indicator of a potential upside. Strong agre
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingGlobeNewswire
- Kymera Therapeutics to Participate in Upcoming May Investor ConferencesGlobeNewswire
- Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
KYMR
Earnings
- 5/2/24 - Beat
KYMR
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/24/24 - Form ARS
- KYMR's page on the SEC website